8-K: Arcellx Announces Positive Phase 2 Data for Anito-cel in Multiple Myeloma, Showcasing High Response Rates and Favorable Safety Profile

Arcellx reported highly positive preliminary results from its Phase 2 iMMagine-1 study of anito-cel, demonstrating a 97% overall response rate and a 62% complete response rate in patients with relapsed or refractory multiple myeloma.

Summary

• Arcellx announced positive preliminary data from its Phase 2 iMMagine-1 study of anito-cel for relapsed or refractory multiple myeloma.
• The study showed a 97% overall response rate (ORR) and a 62% complete response/stringent complete response (CR/sCR) rate in 86 evaluable patients with a median follow-up of 9.5 months.
• 93.1% of patients evaluable for minimal residual disease (MRD) achieved MRD negativity.
• The median progression-free survival (mPFS) and overall survival (OS) were not reached, with 6-month PFS and OS rates at 93.3% and 96.5%, respectively, and 12-month PFS and OS rates at 78.5% and 96.5%, respectively.
• No delayed neurotoxicities were observed in over 150 patients dosed across Phase 1 and iMMagine-1 studies.
• The Phase 1 study of anito-cel demonstrated a 30.2-month median progression-free survival with a median follow-up of 38.1 months.
• The company is also progressing with the iMMagine-3 study, a global Phase 3 trial comparing anito-cel to standard of care in earlier lines of therapy.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical data with strong efficacy and a favorable safety profile, suggesting a very positive outlook for the company and its product. The absence of delayed neurotoxicity is a significant advantage.

Positives

• Anito-cel demonstrated a high overall response rate of 97% in the Phase 2 study.
• The complete response rate of 62% is very promising.
• The absence of delayed neurotoxicities is a significant positive safety finding.
• The 30.2-month median progression-free survival in the Phase 1 study is encouraging.
• The high rate of MRD negativity (93.1%) suggests a deep and durable response.
• The safety profile appears manageable, with most CRS cases being Grade 1.
• The iMMagine-3 study is underway, expanding the potential use of anito-cel to earlier lines of therapy.

Negatives

• Three deaths occurred due to treatment-emergent adverse events, though not all were directly related to anito-cel.
• Cytopenias were common Grade 3 treatment-emergent adverse events, including neutropenia, thrombocytopenia, and anemia.
• 9% of patients experienced any grade ICANS, although all cases resolved without sequelae.

Risks

• The occurrence of treatment-emergent adverse events, including deaths, highlights the risks associated with CAR T-cell therapy.
• Cytopenias are a common side effect and require careful monitoring and management.
• The long-term efficacy and safety of anito-cel need to be further evaluated in ongoing and future studies.
• The success of the iMMagine-3 study is crucial for the broader adoption of anito-cel.

Future Outlook

Arcellx anticipates that anito-cel has the potential to be a best-in-class treatment option for patients with relapsed or refractory multiple myeloma and is progressing with the iMMagine-3 study to further position anito-cel as a differentiated CAR-T treatment option.

Management Comments

• Rami Elghandour, Arcellx's Chairman and CEO, stated that the data from the Phase 1 and iMMagine-1 studies support the conviction that anito-cel has the potential to be a best-in-class treatment option for patients with RRMM.
• Rami Elghandour also expressed gratitude to the team, investors, and collaborators for their contributions to the development of anito-cel.
• Ciara Freeman, M.D., Ph.D., from Moffitt Cancer Center, noted that the data from the iMMagine-1 study demonstrate that anito-cel is a highly active product with impressive depth of responses and an encouraging safety profile.

Industry Context

This announcement is significant in the context of the CAR T-cell therapy landscape for multiple myeloma, where there is a need for more effective and safer treatments. The positive data for anito-cel, particularly the high response rates and lack of delayed neurotoxicity, position it as a potential competitor to existing therapies.

Comparison to Industry Standards

• The 97% ORR and 62% CR/sCR rates for anito-cel in the iMMagine-1 study are highly competitive compared to other approved CAR T-cell therapies for multiple myeloma, such as Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel).
• Abecma has shown ORR rates in the range of 72-73% and CR rates around 25-39% in its pivotal trials, while Carvykti has demonstrated ORR rates of 97-98% and CR rates of 69-83%.
• The absence of delayed neurotoxicity with anito-cel is a notable advantage, as this is a known side effect of some other CAR T-cell therapies.
• The 30.2-month median PFS in the Phase 1 study is also promising, as it suggests a durable response, which is a key goal in multiple myeloma treatment.
• The iMMagine-3 study, comparing anito-cel to standard of care, will be crucial in determining its place in the treatment algorithm for multiple myeloma.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data.
• Patients with relapsed or refractory multiple myeloma may benefit from this promising new treatment option.
• Employees of Arcellx are likely to be motivated by the positive results.
• Kite, as a partner, will also benefit from the success of anito-cel.

Next Steps

• Arcellx will present the data at the 66th ASH Annual Meeting and Exposition on December 9, 2024.
• The company will host a live webcast event with an expert panel of clinicians on December 9, 2024.
• The iMMagine-3 study is underway and will continue to enroll patients.
• Arcellx and Kite will continue to co-develop and co-commercialize anito-cel.

Key Dates

Keywords

anito-cel, multiple myeloma, CAR T-cell therapy, immunotherapy, iMMagine-1, iMMagine-3, relapsed refractory, BCMA, ASH, clinical trial